Intellia Therapeutics Inc
$ 11.91
0.68%
14 Aug - close price
- Market Cap 1,657,699,000 USD
- Current Price $ 11.91
- High / Low $ 12.04 / 11.41
- Stock P/E N/A
- Book Value 5.20
- EPS -3.26
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.30 %
- ROE -0.55 %
- 52 Week High 28.25
- 52 Week Low 7.95
About
Intellia Therapeutics, Inc., a genome editing company, is focused on developing therapies. The company is headquartered in Cambridge, Massachusetts.
Analyst Target Price
$23.94
Quarterly Earnings
| Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-08-06 | 2026-05-11 | 2026-02-26 | 2025-11-06 | 2025-08-07 | 2025-05-08 | 2025-02-27 | 2024-11-07 | 2024-08-08 | 2024-05-09 | 2024-02-22 | 2023-11-09 |
| Reported EPS | -0.8 | -0.81 | -0.83 | -0.92 | -0.99 | -1.1 | -1.27 | -1.34 | -1.52 | -1.12 | -1.46 | -1.38 |
| Estimated EPS | -0.8 | -0.9 | -0.99 | -0.98 | -1.03 | -1.27 | -1.3164 | -1.37 | -1.2 | -1.36 | -1.44 | -1.5 |
| Surprise | 0 | 0.09 | 0.16 | 0.06 | 0.04 | 0.17 | 0.0464 | 0.03 | -0.32 | 0.24 | -0.02 | 0.12 |
| Surprise Percentage | 0% | 10% | 16.1616% | 6.1224% | 3.8835% | 13.3858% | 3.5248% | 2.1898% | -26.6667% | 17.6471% | -1.3889% | 8% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: NTLA
2026-08-13 09:10:51
Wasatch Advisors LP significantly reduced its stake in Intellia Therapeutics Inc. by selling 134,215 shares, decreasing its holdings by 51.3%. Despite this, other institutional investors increased their positions in NTLA. The company currently holds a consensus "Hold" rating from analysts with an average price target of $21.15, and reported a Q2 loss of $0.80 per share, in line with estimates, though revenue missed expectations.
2026-08-12 09:40:53
Royal Bank of Canada significantly increased its stake in Intellia Therapeutics (NASDAQ: NTLA) during the first quarter, now holding 465,499 shares worth approximately $5.97 million. The company reported a quarterly loss of $0.80 per share, meeting estimates, but revenue of $7.66 million missed expectations, declining 46.4% year over year. Institutional investors collectively own 88.77% of NTLA, and analyst ratings are mixed, with a consensus "Hold" rating and an average price target of $20.85.
2026-08-11 19:09:51
Intellia Therapeutics (NTLA) reported Q2 2026 earnings, remaining in a loss-making position, though net loss and loss per share improved year-over-year. Despite recent stock volatility and a mixed long-term record, a narrative analysis suggests NTLA is approximately 50% undervalued with a fair value of $23.94, driven by expectations for its gene-editing pipeline and future approvals. However, the company faces significant risks including high R&D costs and reliance on trial outcomes, and its high P/S ratio indicates market expectations are already elevated.
2026-08-11 05:12:19
Intellia Therapeutics (NASDAQ: NTLA) shares surged 11% despite missing revenue forecasts in its latest quarterly report, with revenues of US$7.7m falling 41% short of expectations. Analysts have subsequently cut 2026 revenue estimates by a substantial amount to US$52.3m, although loss per share estimates remain steady at US$3.18. The average price target has also dropped 8.5% to US$23.94, reflecting concerns about the weaker revenue outlook and continued losses, and the company is expected to underperform the industry's revenue growth.
2026-08-10 12:18:53
Intellia Therapeutics (NASDAQ: NTLA) shares surged 11% following its latest quarterly results, despite revenues falling 41% short of expectations. Analysts have subsequently cut next year's revenue estimates significantly, while holding loss-per-share forecasts steady, leading to an 8.5% drop in the average price target to US$23.94. The company's revenue is now expected to decline by 23% by the end of 2026, underperforming the industry's projected 23% annual growth.
2026-08-10 10:41:04
Intellia Therapeutics, Inc. (NASDAQ:NTLA) recently reported its quarterly results, showing a significant revenue miss of 41% below analyst forecasts, though statutory losses were in line. Following these results, analysts have substantially cut next year's revenue estimates for Intellia Therapeutics by 12% to US$52.3m, while maintaining loss per share forecasts, and consequently, the average price target has fallen by 8.5% to US$23.94. The company is now expected to lag the wider industry's revenue growth, with its own revenues forecast to decline annually by 23% by the end of 2026.
